For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development-Related Party | 18,672 | |||
| Research and development-Nonrelated Party | 106,424 | |||
| General and administrative | 30,508 | |||
| Total operating expenses | 155,604 | |||
| Loss from operations | -155,604 | |||
| Interest income | 17,871 | |||
| Total other income, net | 17,871 | |||
| Net loss before income taxes | -137,733 | |||
| Income tax expense | 217 | |||
| Net loss | -137,950 | |||
| Unrealized gain on marketable securities, net of tax | 243 | |||
| Total other comprehensive income | 243 | |||
| Total comprehensive loss | -137,707 | |||
| Basic EPS | -2.52 | |||
| Diluted EPS | -2.52 | |||
| Basic Average Shares | 54,676,896,000 | |||
| Diluted Average Shares | 54,676,896,000 | |||
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)